Form D · Biotechnology
Vesica Health, Inc.
Irvine, CA · CIK 0002114321
Offering snapshot reported Mar 17, 2026 · SEC filing
- Reported sold
- $4.47M Offering amount: $4.63M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2026 | Initial | $4,467,683 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576760
Amounts include securities issued upon conversion of outstanding convertible securities, warrants issued in connection with the offering and securities issued or to be issued upon exercise of warrants.
Source: Form D, filed Mar 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Laura Caba | Executive |
| Jan Groen | Director |
| Mark Mc Donough | Director |
| Joseph Sollee | Director |
| Christopher Thibodeau | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5 Mason Lane Suite 180
Irvine, CA, 92618
Irvine, CA, 92618